Portopulmonary hypertension.
As a result of the success of orthotopic liver transplantation, there has been increasing interest in the diagnosis and therapeutic options for the pulmonary vascular complications of hepatic disease. These pulmonary vascular complications range from the hepatopulmonary syndrome, which is characterized by intrapulmonary vascular dilatations, to portopulmonary hypertension (POPH), which is characterized by an elevated pulmonary vascular resistance as a consequence of obstruction to pulmonary arterial blood flow. This review concentrates on POPH.
Golbin
Jason M
JM
Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Krowka
Michael J
MJ
D000959:Antihypertensive Agents / Q000627:therapeutic use; D015897:Comorbidity; D004562:Electrocardiography; D011464:Epoprostenol / Q000627:therapeutic use; D020065:Hepatopulmonary Syndrome / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D006975:Hypertension, Portal / Q000453:epidemiology* / Q000503:physiopathology; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D016031:Liver Transplantation; D018579:Patient Selection; D015995:Prevalence; D011651:Pulmonary Artery / Q000000981:diagnostic imaging; D011859:Radiography
D000959:Antihypertensive Agents; D011464:Epoprostenol